Pharmaceuticals Financial News

thematic funds in the said period. SBI Automotive Opportunities Fund, the only auto sector based fund, lost the most at around 12.42% in the last one month. Consumption theme based funds lost 9.18% in the same period.

Subscribe to enjoy similar stories. Pharmaceutical companies are typically rewarded for their innovation with years of market exclusivity before cheaper generics enter the scene. But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost immediately.

Pfizer and Moderna, saw significant declines following the announcement of Robert F. Kennedy Jr. as President-elect Donald Trump’s pick for Secretary of Health and Human Services. Kennedy, a prominent figure in the anti-vaccine movement, has long propagated controversial views and conspiracy theories about vaccines, which could affect the future of public health policies.

Genome Valley at the center of this growth. Notable investments include a Rs. 2,000 crore joint venture between European company KrKA and Laurus Labs to establish pharmaceutical finished products and biopharmaceutical manufacturing facilities in Genome Valley. In addition, Laurus Labs has inaugurated an R&D center with an investment of Rs. 250 crore. Together, these projects are expected to create over 2,800 jobs. Another significant development is the partnership between Japanese pharmaceutical giant Takeda and Biological E, aimed at manufacturing 5 crore doses of the Dengue vaccine annually from Genome Valley. This collaboration positions Hyderabad at the forefront of the global fight against dengue, further solidifying its reputation as the “vaccine capital of the world.”

At Technovation, science takes centre stage, playing a crucial role in the evolving landscape of tobacco alternatives. Philip Morris International (PMI) recently hosted its ninth Technovation event ‘30 years of innovation, 10 years of progress at the Cube, its R&D centre in Neuchâtel, Switzerland. In this context, PMI’s Chief Communications Officer, Dr. Moira Gilchrist, shares her perspective on the critical role of science & technology in driving PMI's commitment to a smoke-free future.

Mankind Pharma Ltd.(up 4.03 per cent), Gland Pharma Ltd.(up 1.78 per cent), Laurus Labs Ltd.(up 1.76 per cent), Granules India Ltd.(up 1.06 per cent) and Aurobindo Pharma Ltd.(up 1.01 per cent) were among the top gainers.

Subscribe to enjoy similar stories. New Delhi: Drugs to treat lifestyle diseases such as hypertension and type 2 diabetes were among the top-selling medicines at the government's generic pharmacies across the country this year, an official said. Telmisartan tablets to treat high blood pressure averaged monthly sales of about 1.41 million strips at the kendras run under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the official aware of the matter said.

Netflix. The series is a great example of mixing comedy and science. It also uncovers the dynamics of personal and professional relationships in its own unconventional way. A closer look will make you realise that the series has some incredible learnings for a person who is serious about making an impact in their own career journey. Here are some significant ones I saw: 1. Embrace continuous learning: The show greatly highlights the advantages of embracing lifelong learning. Two characters, Sheldon Copper and Amy Farrah Fowler, teach us the importance of constantly digging deeper and making discoveries in our fields to stay relevant and make breakthrough developments. Though both these stalwarts have PhD degrees and several accomplishments, they always express the urge to know more and innovate throughout the series. It is one reason why they end up receiving a joint Nobel Prize in the last episode. Hence, whether through formal education or professional interactions, learning is key to grow and thrive.

Akums Drugs and Pharmaceutical, the Delhi-based contract development and manufacturing organisation (CDMO) reported an adjusted net profit of Rs ₹66.7 crore, a 16% year-on-year (YoY) increase from the previous quarter led operational efficiency. Revenue declined 11.9% YoY to ₹1046.6 crore due to lower active pharmaceutical ingredient (API) prices and fluctuating demand.

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Diltiazem Hydrochloride extended-release capsules indicated for the treatment of hypertension. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules of strengths 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, Alembic Pharmaceuticals Ltd (Alembic) said in a statement. These capsules are indicated for the treatment of hypertension. These capsules may be used alone or in combination with other antihypertensive medications. Moreover, Diltiazem Hydrochloride is also indicated for the management of chronic stable angina and angina due to coronary artery spasm, the company said.

S Jaishankar and Russia’s first deputy prime minister Denis Manturov will hold a brainstorming session in Delhi on Tuesday to explore sectors for India’s investments including in Far-Eastern Russia and increasing trade to reduce trade deficit, which is currently in Russia’s favour owing to huge oil exports. They will also discuss measures to smoothen the rupee-ruble payment mechanism. While the mechanism is functioning, large volumes of transactions often face delay due to limitations of the transaction mechanism. Also on the agenda is a free trade agreement between India and Eurasian Economic Union, according to people familiar with the matter. Besides, Russia is exploring to invest in India through some of the accumulated rupees, they said. “On November 12, in New Delhi, Denis Manturov jointly with Minister of External Affairs of India Dr Subrahmanyam Jaishankar will hold the 25th session of the Intergovernmental Russian-Indian Commission on Trade, Economic, Scientific, Technical and Cultural Cooperation. As part of his visit, the First Deputy Prime Minister also has a number of bilateral meetings planned,” said a statement issued by the Russian Embassy in India.

Subscribe to enjoy similar stories. Wall Street’s verdict is clear: A second Trump presidency is likely to deliver a blow to an export-dependent European Union that is struggling with sclerotic economic growth and ever-multiplying political crises. Whether it will finally spark some change is the question for patient investors.

The company posted net profit of Rs 752 crore in the corresponding quarter of previous year. On a quarter-on-quarter (QoQ) basis the net profit declined 11%.

Subscribe to enjoy similar stories. While the spotlight often shines on India's well-known investors, there's a silent group of investment gurus quietly accumulating wealth and delivering impressive returns. These lesser-known investors, often operating under the radar, are worth watching closely.

Wall Street dealmakers and corporate leaders expect the flood gates to open on merger and acquisition activity after President-elect Donald Trump takes office in January.

The company reported Rs 133 crore in net profit in Q2FY23.

Emcure Pharmaceuticals on Thursday reported a 38.2% year-on-year (YoY) increase in net profit to Rs.202 crore in Q2FY25 led by strong performance of domestic and international business The Pune-based drug maker posted Rs 145.8 crore in the same period last year.

Lupin reported a bigger-than-expected rise in second-quarter profit on Thursday, driven by strong demand for its respiratory and diabetes management drugs. Consolidated net profit of the company, which makes biosimilars and active pharmaceutical ingredients, rose to 8.53 billion rupees (about $101 million) for the quarter ended Sept. 30, up about 74% from a year earlier and higher than analysts' estimates of 7.29 billion rupees, as per data compiled by LSEG.

buy call on Gland Pharma with a target price of Rs 1970. The current market price of Gland Pharma is Rs 1786.4. Gland Pharma, incorporated in 1978, is a Small Cap company with a market cap of Rs 29372.76 crore, operating in the pharmaceuticals sector. Gland Pharma's key products/revenue segments include Pharmaceuticals, Sale of services, Export Incentives for the year ending 31-Mar-2024.

Indian exporters may face high customs duties for goods like automobiles, textiles and pharmaceuticals if the new US administration decides to pursue the 'America First' agenda, opined trade experts. Experts also said that Trump could also tighten H-1B visa rules, impacting costs and growth for Indian IT firms.

Subscribe to enjoy similar stories. NEW DELHI : With Donald Trump, the Republican nominee and former US president, leading the US presidential race, India's trade ties with the country—one of the few with which India has a merchandise trade surplus—are likely set for a paradigm shift.